A. Hauschild, J. Grob, L. V. Demidov, T. Jouary, R. Gutzmer et al., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet Lond Engl. 28 juill, vol.380, issue.9839, pp.358-65, 2012.

P. B. Chapman, A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, vol.364, issue.26, pp.2507-2523, 2011.

C. Robert, B. Karaszewska, J. Schachter, P. Rutkowski, A. Mackiewicz et al., Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

,

D. Sur,

A. Pages, S. Foulon, Z. Zou, L. Lacroix, F. Lemare et al., The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial, Genet Med Off J Am Coll Med Genet. 1 de?, 2016.

C. Massard, S. Michiels, C. Ferte?, L. Deley, M. Lacroix et al., High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial, Cancer Discov. juin, vol.7, issue.6, pp.586-95, 2017.

F. Andre?, T. Bachelot, F. Commo, M. Campone, M. Arnedos et al.,

, Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre

, Lancet Oncol. mars, vol.15, issue.3, pp.267-74, 2014.

L. Tourneau, C. Kamal, M. Tsimberidou, A. Bedard, P. Pierron et al., Treatment Algorithms Based on Tumor Molecular ProHiling: The Essence of Precision Medicine Trials, J Natl Cancer Inst. avr, vol.108, issue.4, 2016.

M. Schwaederle, M. Zhao, J. J. Lee, V. Lazar, B. Leyland-jones et al., Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis, JAMA Oncol. 6 juin, 2016.

T. C. Knepper, G. C. Bell, J. K. Hicks, E. Padron, J. K. Teer et al., Key Lessons Learned from MofHitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience, The Oncologist. fevr, vol.22, issue.2, pp.144-51, 2017.

C. G. Kaderbhai, R. Boidot, F. Beltjens, S. Chevrier, L. Arnould et al., Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer, Oncotarget. 26 mars, vol.7, issue.17, pp.24860-70, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01440517

S. Harada, R. Arend, Q. Dai, J. A. Levesque, T. S. Winokur et al., Implementation and utilization of the molecular tumor board to guide precision medicine, Oncotarget. 22 aou?t, vol.8, issue.34, pp.57845-54, 2017.

H. Beltran, K. Eng, J. M. Mosquera, A. Sigaras, A. Romanel et al., Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response, JAMA Oncol. juill, vol.1, issue.4, pp.466-74, 2015.

J. Laskin, S. Jones, S. Aparicio, S. Chia, C. Ch'ng et al., Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Cold Spring Harb Mol Case Stud, vol.1, p.570, 2015.

B. A. Parker, M. Schwaederle?, M. D. Scur, S. G. Boles, T. Helsten et al.,

, Breast Cancer Experience of the Molecular Tumor Board at the University of California, J Oncol Pract, vol.11, issue.6, pp.442-451, 2015.

M. V. Ortiz, R. Kobos, M. Walsh, E. K. Slotkin, S. Roberts et al., Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center, Pediatr Blood Cancer, vol.63, issue.8, pp.1368-74, 2016.

, Phase II study of intravenous vinHlunine after failure of Hirst-line vinorelbine based regimen for advanced breast cancer, Breast Edinb Scotl. fevr, vol.22, issue.1, pp.58-63, 2013.

C. Basse, C. Morel, M. Alt, M. P. Sablin, C. Franck et al., Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer. ESMO Open, vol.3, p.28, 2018.

X. Liao, P. Lochhead, R. Nishihara, T. Morikawa, A. Kuchiba et al., Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival, N Engl J Med, vol.367, issue.17, pp.1596-606, 2012.

J. Guo, L. Si, Y. Kong, K. T. Flaherty, X. Xu et al., Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or ampliHication, J Clin Oncol Off J Am Soc Clin Oncol. 20 juill, vol.29, issue.21, pp.2904-2913, 2011.

R. D. Carvajal, C. R. Antonescu, J. D. Wolchok, P. B. Chapman, R. Roman et al., KIT as a therapeutic target in metastatic melanoma, JAMA. 8 juin, vol.305, issue.22, pp.2327-2361, 2011.

H. Tu, E. Ke, Y. Sun, Y. Yan, H. Zheng et al., A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer, Lung Cancer Amst Neth. de?, vol.114, pp.96-102, 2017.

H. Shi, G. Moriceau, X. Kong, R. C. Koya, R. Nazarian et al., Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors, Cancer Discov. mai, vol.2, issue.5, pp.414-438, 2012.

I. R. Watson, L. Li, P. K. Cabeceiras, M. Mahdavi, T. Gutschner et al., The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF, Cancer Res. 1 sept, vol.74, issue.17, pp.4845-52, 2014.

S. I. Nikolaev, D. Rimoldi, C. Iseli, A. Valsesia, D. Robyr et al., Exome sequencing identiHies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma, Nat Genet. 25 de?, vol.44, issue.2, pp.133-142, 2011.

L. J. Tafe, I. P. Gorlov, F. B. De-abreu, J. A. Lefferts, X. Liu et al., Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center, The Oncologist. sept, vol.20, issue.9, pp.1011-1019, 2015.

O. Tredan, Q. Wang, D. Pissaloux, P. Cassier, A. De-la-fouchardiere et al., Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProHiLER trial, Ann Oncol Off J Eur Soc Med Oncol. 13 mars, 2019.

C. J. Presley, D. Tang, P. R. Soulos, A. C. Chiang, J. A. Longtine et al., Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting, JAMA, vol.320, issue.5, pp.469-77, 2018.

Z. R. Chalmers, C. F. Connelly, D. Fabrizio, L. Gay, S. M. Ali et al., Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

, Genome Med, vol.19, issue.1, p.34, 2017.

A. Zehir, R. Benayed, R. H. Shah, A. Syed, S. Middha et al., Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients, Nat Med. juin, vol.23, issue.6, pp.703-716, 2017.

M. Nishino, N. H. Ramaiya, H. Hatabu, and F. S. Hodi, Monitoring immune-checkpoint blockade: response evaluation and biomarker development, Nat Rev Clin Oncol, vol.14, issue.11, pp.655-68, 2017.

M. Yarchoan, A. Hopkins, and E. M. Jaffee, Tumor Mutational Burden and Response Rate to PD-1 Inhibition, N Engl J Med, vol.21, issue.25, pp.2500-2501, 2017.

E. M. Van-allen, D. Miao, B. Schilling, S. A. Shukla, C. Blank et al., Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, vol.350, issue.6257, pp.207-218, 2015.

, Mismatch repair deHiciency predicts response of solid tumors to PD-1 blockade, 2018.

N. A. Rizvi, M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov et al., Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science. 3 avr, vol.348, issue.6230, pp.124-132, 2015.